Curaleaf Holdings is an international cannabis company headquartered in Stamford, Connecticut. It operates U.S. dispensaries and production facilities under state licenses and runs a separate international medical-cannabis business. The company trades as CURA on the Toronto Stock Exchange and CURLF on the OTCQX. Its scale spans retail, cultivation, manufacturing and brand distribution, but legal access and product selection remain specific to each jurisdiction.
Origins and ownership
The company began as PalliaTech in 2010 and adopted the Curaleaf name in 2018. Boris Jordan became an early investor, later executive chairman, and added the chief-executive role in 2024. Curaleaf expanded through licensing, construction and acquisitions, creating a network of dispensaries and production facilities. Store ownership and counts change over time, so dated regulatory filings are better reference points than undated footprint claims.
Where it operates
Curaleaf is both a dispensary name and a product brand. The wider portfolio includes Select, Grassroots, Find, Anthem and JAMS, with formats such as flower, pre-rolls, vapor products, concentrates and edibles varying by market. A Curaleaf store also carries products made by other licensed companies. The responsible producer, ingredients and testing information for a particular item appear on its package.
The company’s second-quarter 2026 release reported 174 operated or managed dispensaries at quarter end, including 73 in Florida. It reported 176 after the quarter, with 75 in Florida. Those figures are snapshots rather than permanent totals. The same release described a Dark Heart launch across 11 states, illustrating how a shared brand can reach several markets through separate state-regulated supply chains.
Medical patients and adult-use customers should begin with the rules and licensed sellers in their location. Store menus can change quickly, while the physical label identifies the manufacturer, batch, potency, dates and warnings. Anyone holding the recalled UK oil should match the batch number and follow the regulator or pharmacy instructions. Health questions belong with a qualified clinician rather than a retail menu.
International operations
Curaleaf International operates in medical-cannabis markets outside the United States. In 2026 Curaleaf completed the buyout of the remaining interest in Four 20 Pharma, taking full ownership of that business. Medical products, prescriptions, manufacturing standards and access rules differ by country. A product name used in the United Kingdom or Europe should not be assumed to match a similarly named U.S. adult-use item.
Recognition
For the quarter ended June 30, 2026, Curaleaf reported $340.1 million in revenue, $12.5 million in net income and $70.1 million in adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure, and the filing includes the company’s reconciliation and definitions. These results describe the corporate period; they do not indicate the quality, availability or safety of an individual retail product.
Recent activity
On March 12, 2026, the United Kingdom’s Medicines and Healthcare products Regulatory Agency issued a Class 2 recall for three batches of Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD in 30ml bottles. A stability study found THC below the acceptable level. The notice names specific batch numbers and actions for healthcare professionals and patients; it does not cover every Curaleaf product.